(Q48364662)

11 February 2018

review article

1 reference

title

Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? (English)

1 reference

11 February 2018

0 references

DeQuardo JR

1

1 reference

11 February 2018

Tandon R

series ordinal

2

1 reference

11 February 2018

publication date

1 May 1998

1 reference

11 February 2018

Journal of Psychiatric Research

published in

1 reference

11 February 2018

volume

32

1 reference

11 February 2018

issue

3-4

1 reference

11 February 2018

page(s)

229-242

1 reference

11 February 2018

Cost-effectiveness of clozapine. A UK clinic-based study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Neurocognitive impairment in schizophrenia and how it affects treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Overview: maintenance therapy in psychiatry: I. Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Oral versus depot administration of neuroleptics in relapse prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Is there cognitive decline in schizophrenia? A cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

New atypical antipsychotic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Changes in caudate volume with neuroleptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Understanding schizophrenia: the impact of novel antipsychotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Neuroleptics and the Natural Course of Schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2898%2900024-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3956(98)00024-7

1 reference

11 February 2018

1 reference

11 February 2018